Salud
13 sa önceResumen IA
日本人の食事リズム、4つの型に分類されることを研究が明らかに
東京大学などの研究者らが発表した論文によると、日本人の食事リズムは「勤務日に朝食早め・多め型」「休日に朝食抜き型」「間食多め・夕食少なめ型」「昼食多め・夕食早め型」の4つに分類される。これらの型は個人の属性と関連するが、食事の質や肥満との直接的な関連は統計的に有意ではなかった。
I
ITmediaobesity
Estable45 noticias17 fuentesÚltima actualización: 13 sa önce
Últimas noticias
En desarrollo
Business·16 sa önceResumen IA
India's Health Challenge: Obesity and Sedentary Lifestyles Threaten Economic Growth
India's Chief Economic Advisor V. Anantha Nageswaran highlights rising obesity and sedentary lifestyles as a greater concern than aging before wealth. This health challenge impacts productivity and economic growth, with only 6% of Indians exercising. He urges incorporating physical activity into daily routines for "hidden growth potential" in Viksit Bharat.
E
Economic Times
En desarrollo
Salud·20 sa önceResumen IA
Telehealth Companies Managing Obesity Drugs Often Prioritize Cost Savings Over Patient Needs
Telehealth companies hired by employers to manage obesity drug costs are increasingly criticized for prioritizing cost-cutting over patient care. Patients report being forced to try less effective generic drugs or face denial of access to crucial medications like Zepbound and Wegovy, leading to frustration and weight regain.
N
NPR NewsEn desarrollo
Salud·1 g önceResumen IA
Telehealth Companies Managing Obesity Drug Costs Face Scrutiny
Telehealth companies hired by employers to manage obesity drug costs are facing criticism for potentially limiting patient access to medications like Zepbound and Wegovy. Patients report being forced to try generic drugs first or facing hurdles that lead to out-of-pocket expenses, while doctors express concern over these companies offering medical advice outside their scope.
N
NPR News
Salud
1 g önceResumen IA
營養師：減肥不只靠節食 餐前喝水助控制體重
營養師蕭瑋霖指出，研究顯示餐前30分鐘喝500ml水，有助於體重控制。此方法透過物理佔位和血漿滲透壓變化抑制食慾，尤其對55歲以上及快食族群效果顯著。無糖氣泡水效果近似白開水，但含糖飲料無此效果。
自
自由时报
En desarrollo
Salud·1 g önceResumen IA
Drugmakers Envision Future of Obesity Treatments Beyond GLP-1s
Drugmakers are exploring new obesity treatments beyond GLP-1s, including less frequent shots and pills with fewer side effects. Eli Lilly's experimental drug retatrutide showed significant weight loss, while competitors like Novo Nordisk, Structure Therapeutics, AstraZeneca, Pfizer, and Amgen are developing new oral and injectable options. The market is expected to grow significantly, with pricing and insurance coverage being key factors.
C
CNBC US Markets
Salud
3 g önceResumen IA
UK Approves Wegovy Weight-Loss Pill, Expanding Obesity Treatment Options
The UK's MHRA has approved Wegovy, the first GLP-1 receptor agonist tablet for weight loss, making the UK the third country to authorize the pills. This expands treatment options for adults with obesity or overweight with related health conditions.
G
Guardian UKSalud
3 g önceResumen IA
UK Approves First GLP-1 Receptor Agonist Tablet for Weight Management
The UK's MHRA has approved the first GLP-1 receptor agonist tablet, semaglutide (Wegovy), for weight loss and management. This daily pill offers a more convenient alternative to weekly injections for adults with obesity or those overweight with weight-related conditions.
T
Times of India
Salud
4 g önceResumen IA
AstraZeneca's anti-obesity pill shows encouraging results
AstraZeneca's oral anti-obesity drug, elecoglipron, has shown promising results in a study, demonstrating a good safety and tolerability profile while leading to significant weight loss and appetite reduction.
L
Le Figaro Actualités
Salud
5 g önceResumen IA
GLP-1 Obesity Treatments Show Promise in Reducing Cancer Risk
Recent studies suggest GLP-1 obesity treatments may reduce cancer risk, showing correlation with decreased incidence in 6 out of 7 cancers, potentially through anti-inflammatory effects beyond weight loss.
N
NPR News
En desarrollo
Business·04.06.2026Resumen IA
Anti-obesity drugs impact consumer habits, sparking economic shifts
Anti-obesity drugs like GLP-1 analogues are altering consumer behavior, affecting sales of snacks, sodas, and meal replacements. Companies like Nestlé and Danone are acquiring meal substitute startups to adapt to these changes.
L
Le Monde
En desarrollo
Política·04.06.2026Resumen IA
KMT Candidate's Obesity Claim Debunked by DPP Challenger in Kaohsiung
KMT Kaohsiung mayoral candidate Ke Chih-en claimed the city has the highest adult obesity rate (41.3%). DPP candidate Yin Li refuted this, stating Kaohsiung's rate is now the second lowest (38.1%) and criticized Ke for factual errors about local landmarks and businesses.
自
自由时报Salud
03.06.2026Resumen IA
Four Health Markers That May Offer a Broader Understanding of Cardiovascular Risk
Cardiologists suggest focusing on four markers beyond LDL cholesterol for a comprehensive cardiovascular risk assessment: ApoB, hs-CRP, insulin resistance, and abdominal obesity. These factors provide insights into harmful particle counts, inflammation, metabolism, and fat distribution, aiding earlier detection of potential heart attacks and strokes.
T
Times of IndiaEn desarrollo
Salud·03.06.2026Resumen IA
France to Reimburse Obesity Treatments Wegovy and Mounjaro from Mid-June
Starting mid-June, France will reimburse 65% of Wegovy and Mounjaro obesity treatments for eligible patients. While patients report effectiveness, high costs and strict eligibility criteria, excluding those with IMC below 35 or 40 without comorbidities, are major concerns.
2
20 MinutesEn desarrollo
Salud·02.06.2026Resumen IA
India Faces Rising Tide of Obesity and Diabetes, NFHS-6 Data Reveals
India's NFHS-6 survey shows a significant rise in obesity and high blood sugar levels among adults. Nearly 1 in 3 women and over 1 in 4 men are overweight or obese, with southern and coastal regions emerging as hotspots for these lifestyle diseases.
T
Times of India
En desarrollo
Salud·02.06.2026Resumen IA
Weight-loss drugs may cut cancer risk by 30%, studies suggest
New studies presented at a major oncology conference suggest GLP-1 weight-loss drugs could reduce cancer risk by 30%. Research indicates they may lower the likelihood of developing breast cancer, decrease mortality risk in breast cancer patients, and reduce the spread of various cancers.
G
Guardian International
Urgente
Crime·02.06.2026Resumen IA
Obesity surgeon Reza Adib suspended amid rape charges
Prominent obesity surgeon Vahid Reza Adib, 65, has had his medical registration suspended effective June 2, 2026, due to rape charges. He faces three counts of rape, two of deprivation of liberty, and one of sexual assault.
A
ABC Top Stories
En desarrollo
Salud·25.05.2026Resumen IA
Retatrutide: The New Obesity Drug Promising 30% Weight Loss
Retatrutide, a new obesity drug from Eli Lilly, has shown a 30% weight loss in trials, surpassing previous drugs like Ozempic. It mimics GLP-1 and other hormones, offering benefits beyond weight loss, including anti-inflammatory effects.
E
El MundoEn desarrollo
Salud·24.05.2026Resumen IA
Retatrutide: The New Obesity Drug Promising 30% Weight Loss and Broader Health Benefits
Retatrutide, a new obesity drug, has shown a 30% weight loss in trials, surpassing previous drugs. Experts highlight its broader benefits beyond weight loss, including reduced inflammation and improved cardiovascular and kidney function, attributing these to its multi-organ receptor action.
E
El Mundo
Urgente
Salud·24.05.2026Resumen IA
Childhood obesity: Waist-to-height ratio a key indicator for metabolic risks in adolescents, warns nutritionist
A nutritionist warns that a waist-to-height ratio exceeding 0.5 in children as young as 12 can signal accumulating metabolic risks, including abdominal obesity, high cholesterol, and elevated blood sugar, urging parents to monitor these indicators beyond just weight.
自
自由时报
En desarrollo
Salud·22.05.2026Resumen IA
Domestic obesity drug market triples in a year; 1 in 3 adults obese
South Korea's obesity drug market has surged over threefold in a year, reaching 819.5 billion won in 2024. With 34.4% of adults obese, domestic companies like Hanmi Pharmaceutical and Celltrion are accelerating development of GLP-1 based drugs, aiming to compete on price and reduced side effects.
연
연합뉴스
En desarrollo
Salud·22.05.2026Resumen IA
GLP-1 Drugs May Slow Cancer Progression, New Study Suggests
A new study suggests GLP-1 drugs, known for weight loss and diabetes treatment, may slow the progression of certain obesity-related cancers. Comparing GLP-1 users to those on DPP-4 inhibitors, researchers found reduced cancer spread in lung, breast, colorectal, and liver cancers.
T
The Independent World
Urgente
Salud·20.05.2026Resumen IA
China's School-Age Children Face Rising Obesity and Hidden Hunger
China's school-age children face a dual challenge of overnutrition and hidden hunger, with obesity rates reaching 19%. Experts warn of rising chronic diseases in youth due to poor diets and lack of exercise, urging adherence to updated dietary guidelines for different age groups.
中
中国新闻网
Política
20.05.2026Resumen IA
Donald Trump's Investments in Eli Lilly Amidst Obesity Drug Access Expansion
Financial disclosures reveal hundreds of thousands of dollars invested in Eli Lilly on Donald Trump's behalf in early 2026, coinciding with his administration's initiatives to expand access to obesity treatments like those produced by Lilly.
G
Guardian Business